

Section 1. Identifying Infor	mation							
Given Name (First Name) Eric	2. Surname (Last Name) Bateman	3. Effective Date (07-August-2008) 04-September-2013						
4. Are you the corresponding author?	✓ Yes No							
5. Manuscript Title Lack of clinically relevant difference in combination therapy and monotherapy in COPD								
6. Manuscript Identifying Number (if you know it) ERJ-01435-2013								

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration f	or Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			√	University of Cape Town Lung Institute	Payment for participation in clinical trials	×
						ADD
2. Consulting fee or honorarium	\checkmark					X ADD
3. Support for travel to meetings for the study or other purposes			/	University of Cape Town Lung Institute		×
						ADD
 Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like 	✓					×
						ADD
Payment for writing or reviewing the manuscript	\checkmark					×
						ADD



The Work Under Consideration for Publication							
Туре	No		Money to Your Institution*	Name of Entity	Comments**		
 Provision of writing assistance, medicines, equipment, or administrative support 	✓					×	
						ADD	
7. Other	1					×	
						ADD	

Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work							
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments		
1. Board membership		√		Boehringer Ingelheim	Asthma & Respiratory	×	
1. Board membership		√		AstraZeneca	Asthma & COPD board	×	
1. Board membership		\checkmark		Elevation Pharma	COPD drug development		
1. Board membership		\checkmark		Napp Pharma	Trial design	×	
1. Board membership		√		Novartis	COPD drug development	×	
1. Board membership		√		Almirall	COPD drug development	×	
1. Board membership		√		Forest	COPD drug development	×	
1. Board membership		\checkmark		Merck	Asthma treatments	×	
1. Board membership		\checkmark		Takeda	COPD & asthma studies	×	
1. Board membership		V		Glaxo SmithKline	Asthma trial design	×	
1. Board membership		\checkmark		Pfizer	COPD drug development	×	

Bateman 3

^{*} This means money that your institution received for your efforts on this study.

^{**} Use this section to provide any needed explanation.



Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
) Committee on				Navigant Canadian		AE
2. Consultancy	Ш	✓		Navigant Consulting	Health economic	
2. Consultancy		✓		IMS Consulting Group	outcomes	
2. Consultancy		✓		ALK-Abello	Trial design	
2. Consultancy		√		Almirall	Trial design	
2. Consultancy		\checkmark		Hoffmann la Roche	Drug safety monitoring board	
2. Consultancy		√		ICON	Study Steering Committee	
2. Consultancy		√		Actelion	Trial design	
						A
. Employment	1					
			_			A
. Expert testimony	\checkmark					^
i. Grants/grants pending	П		✓	Actelion	Multicentre clinical trial	A
5. Grants/grants pending	П	П	✓	Aeras	Vaccine trial	
5. Grants/grants pending			✓	Almirall	Multicentre clinical trial	
5. Grants/grants pending	$\overline{\Box}$	П	✓	Boehringer Ingelheim	Multicentre clinical trial	
. Grants/grants pending			✓	Chiesi	Multicentre clinical trial	
6. Grants/grants pending			/	GlaxoSmithKline	Multicentre clinical trial	
. Grants/grants pending			✓	Merck	Multicentre clinical trial	
. Grants/grants pending			\checkmark	Novatis	Multicentre clinical trial	
6. Grants/grants pending			✓	Nycomed	Multicentre clinical trial	
6. Grants/grants pending			√	Hoffman la Roche	Multicentre clinical trial	
6. Grants/grants pending			\checkmark	Genentech	Multicentre clinical trial	
						A
s. Payment for lectures including service on speakers bureaus		\checkmark		AstraZeneca		
5. Payment for lectures including service on speakers bureaus		✓		AlkAbello		,



6.	Payment for lectures including service on speakers bureaus		✓	Chiesi		×
6.	Payment for lectures including service on speakers bureaus		√	Boehringer Ingelheim		×
6.	Payment for lectures including service on speakers bureaus		\checkmark	GlaxoSmithKline		×
6.	Payment for lectures including service on speakers bureaus		/	Takeda		×
6.	Payment for lectures including service on speakers bureaus		\checkmark	Novartis		×
6.	Payment for lectures including service on speakers bureaus		\checkmark	Pfizer		×
						ADD
7.	Payment for manuscript preparation	\checkmark				×
						ADD
8.	Patents (planned, pending or issued)	√				×
						ADD
9.	Royalties	\checkmark				×
						ADD
10.	Payment for development of educational presentations		\checkmark	Indegene Lifesciences Ltd	Teaching materials	×
10.	Payment for development of educational presentations		\checkmark	Novartis	Teaching materials	×
						ADD
11.	Stock/stock options	\checkmark				×
						ADD
12.	Travel/accommodations/ meeting expenses unrelated to activities listed**	\checkmark				×
						ADD
13.	Other (err on the side of full disclosure)	\checkmark				×
						ADD

^{*} This means money that your institution received for your efforts.

^{**} For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Carrie	
Section 4.	Other relationships
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
✓ Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
	he Board of the Global Initiative for Asthma (GINA) he ATS/ERS Task Force on Severe Asthma nitiative
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
	Hide All Table Rows Checked 'No'

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.